Does exemestane (Aromasin) cause an increase in cholesterol and triglyceride levels?

Yes, Aromasin (exemestane) can cause increases in cholesterol and triglyceride levels, though the effects are complex and differ from other aromatase inhibitors.

Based on FDA drug labeling and clinical trial data, exemestane causes a decrease in HDL cholesterol (the "good" cholesterol) but has mixed effects on other lipid parameters. 1

Specific Lipid Effects of Exemestane

HDL Cholesterol (Decreases)

• Plasma HDL cholesterol decreased by 6-9% in exemestane-treated patients compared to placebo 1
• This HDL reduction is clinically significant and consistently observed across multiple studies 2, 3
• The decrease in HDL occurred regardless of whether patients were taking lipid-lowering medications 2

Triglycerides (Generally Favorable)

Interestingly, exemestane appears to lower or have neutral effects on triglycerides, which differs from other hormonal therapies:

• Exemestane lowered triglyceride levels over time, while tamoxifen increased them 4
• This beneficial effect on triglycerides was consistent across multiple studies 4, 5, 6

Total and LDL Cholesterol (Variable)

• Total cholesterol, LDL cholesterol, and apolipoprotein levels remained largely unchanged in FDA trials 1
• However, some studies showed increases in LDL when patients switched from tamoxifen to exemestane, likely due to tamoxifen washout rather than exemestane itself 2

Clinical Monitoring Recommendations

You should monitor lipid panels in patients taking exemestane:

• Obtain baseline fasting lipid panel before starting treatment
• Recheck at 3-6 months after initiation
• Continue monitoring periodically, especially in patients with pre-existing cardiovascular risk factors 7

Important Caveats

The decrease in HDL cholesterol does not necessarily translate to increased cardiovascular risk because:

• The atherogenic indices (TC:HDL ratio and ApoA1:ApoB ratio) remained stable during exemestane treatment 4, 5
• The beneficial reduction in triglycerides may offset the HDL decrease
• No significant increase in cardiovascular events was observed in clinical trials, though follow-up was limited 1

Comparison to Other Aromatase Inhibitors

Exemestane (steroidal AI) has a more favorable lipid profile than nonsteroidal AIs (anastrozole, letrozole):

• Nonsteroidal AIs cause significantly higher increases in triglycerides and total cholesterol 8
• The cumulative incidence of lipid events at 24 months was 25.3% with steroidal AIs versus 37.0% with nonsteroidal AIs 8
• Letrozole specifically increased LDL cholesterol, while exemestane did not 2

Management Approach

If lipid abnormalities develop on exemestane:

1. First-line: Implement lifestyle modifications (diet, exercise, weight management)
2. Second-line: Consider statin therapy if cardiovascular risk is elevated
   • Use hydrophilic statins (pravastatin, fluvastatin) preferentially as they don't interact with exemestane metabolism 9
   • Lipophilic statins (atorvastatin, simvastatin) can be used cautiously at doses ≤20 mg/day 9
3. Avoid: Bile acid sequestrants if patient is on other medications, as they can interfere with absorption 9

Do not discontinue exemestane solely for lipid changes unless they are severe and refractory to treatment, as the oncologic benefit typically outweighs the lipid risks in appropriate patients.